Philosophy
Without our partners, both present and future, we will not be able to achieve the goals we have set before us. Particularly in the context of the fight against cancer, we know that a single therapy will not provide the ‘silver bullet’. Although we believe the UNITE® platform will play a fundamental role in the immuno-oncology landscape, we’ll need to participate in an orchestrated effort of multiple players.
Collaborations
The scale and scope of our partnerships provides new avenues and resources to develop novel nucleic acid immunotherapies. We maintain collaborations with academic institutions and hospitals, including Dana Farber Cancer Institute, University of Washington and Fred Hutchinson Cancer Research Center and the University of Florida, which help us realize our mission of commercializing UNITE® immunotherapies for various human diseases. We are interested in research collaborations to further elucidate the mechanism of action of nucleic acid-based therapies and which advance clinical testing of promising vaccine concepts.
Partner With Us
Immunomic Therapeutics’ domain expertise is in vaccine design, development, manufacturing and testing. In collaborating with Immunomic, expect an unflinching commitment to scientific integrity and an unrelenting desire to find relevant solutions for the health problems that threaten quality of life. The company’s resources can help accelerate research and development, moving from lead to product candidate in as little as three months. To advance our mission, we invite all types of collaborations.